2 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOPending
The primary objective of this study is to assess the effectiveness and cost-effectiveness in terms of the number of surgeries prevented of a combination therapy versus usual care.The secondary objective of this study is to assess the effectiveness…